Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083
In a randomized clinical trial, pre-exposure prophylaxis (PrEP) with long-acting cabotegravir (CAB-LA) had a better bone safety profile than tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) over 105 weeks. For individuals with low bone mineral density or other fracture risk factors, CAB-LA PrEP should be considered over TDF-based PrEP. Clinical Trials Registration. clinicaltrials.gov (NCT02720094).
Authors
- Maryam Warsi (ORCID: https://orcid.org/0000-0002-8628-1821)
- Ricardo Vasconcelos (ORCID: https://orcid.org/0000-0002-9753-0563)
- Beatriz Gilda Jegerhorn Grinsztejn (ORCID: https://orcid.org/0000-0003-3692-5155)
- Raphael J. Landovitz (ORCID: https://orcid.org/0000-0002-1442-714X)
- Marybeth McCauley
- James F. Rooney (ORCID: https://orcid.org/0000-0003-3261-0711)
- Nittaya Phanuphak (ORCID: https://orcid.org/0000-0002-0036-3165)
- Todd T. Brown (ORCID: https://orcid.org/0000-0001-8599-278X)
- Philip A. Sullivan
- Temitope Oyedele
- Brett Hanscom (ORCID: https://orcid.org/0000-0003-0618-2979)
- Alex R. Rinehart
- Robert F. Arao
Institutions
- Family Health International 360 (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Universidade de São Paulo (BR)
- Johns Hopkins Medicine (US)
- Fred Hutch Cancer Center (US)
- HIV Netherlands Australia Thailand Research Collaboration (TH)
- Gilead Sciences (United States) (US)
- Instituto Evandro Chagas (BR)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1093/cid/ciaf221
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00